Bessemer Group Inc. Has $3.16 Million Position in Pfizer Inc. (NYSE:PFE)

Bessemer Group Inc. reduced its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 15.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 119,250 shares of the biopharmaceutical company's stock after selling 21,371 shares during the period. Bessemer Group Inc.'s holdings in Pfizer were worth $3,164,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the 4th quarter valued at about $28,000. Noble Wealth Management PBC acquired a new position in Pfizer during the fourth quarter worth about $31,000. Finally, Curio Wealth LLC purchased a new position in Pfizer in the fourth quarter valued at about $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is currently owned by insiders.

Remove Ads

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PFE. Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. UBS Group dropped their price target on Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a research report on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.07.

Pfizer Stock Performance

PFE stock traded up $0.19 during midday trading on Monday, hitting $22.10. 61,888,490 shares of the company traded hands, compared to its average volume of 40,318,766. The business has a 50 day simple moving average of $25.25 and a 200-day simple moving average of $26.38. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock has a market capitalization of $125.34 billion, a price-to-earnings ratio of 15.67, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period last year, the business earned $0.10 earnings per share. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.